^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    TrkB receptor inhibitor

    Related drugs:
    9ms
    New case report – successful limb salvage of a child with infantile fibrosarcoma using Larotrectinib @drshubhamsahni @samdoc_mamc https://t.co/g0f4GGrWFh (@ecancer)
    Vitrakvi (larotrectinib)
    10ms
    Fantastic learning programme from @DrEzraCohen ! Updates on #NTRK fusions in #thyroidcancer with a focus on: ✅Treatments such as #entrectinib and #larotrectinib ✅ Histopathology ✅Efficacy and safety of treatment Watch and download the slides here👇 https://t.co/KEY6lBsvUT (@PresOnc_Connect)
    Clinical
    |
    NTRK (Neurotrophic receptor tyrosine kinase)
    |
    NTRK fusion
    |
    Vitrakvi (larotrectinib) • Rozlytrek (entrectinib)
    11ms
    #ASCO23 | Hall A | Sunday 8am CT Long-term Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase (TRK) Fusion Lung Cancer Jessica Lin, MD (@JessicaJLinMD) ➡️ https://t.co/I4j2RKV3WG @ASCO #MGCCatASCO23 (@MGHCancerCenter)
    Clinical
    |
    Vitrakvi (larotrectinib)
    11ms
    🎙️ In this JCO PO Conversations podcast episode, host @thenasheffect speaks with @alexdrilon about his JCO PO article "Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion–Positive Lung Cancers" 🎧 Take a listen ➡️ https://t.co/JEuabTW4St (@JCOPO_ASCO)
    Clinical
    |
    Vitrakvi (larotrectinib)
    12ms
    Dr. @RobertoFerrara_ at #RomeLung23 discusses #NTRK as a viable target in NSCLC with two approved drugs: larotrectinib and entrectinib. Still unraveling primary and acquired resistance but newer agents like repotrectinib showing promise. (@StephenVLiu)
    Preclinical
    |
    NTRK (Neurotrophic receptor tyrosine kinase)
    |
    Vitrakvi (larotrectinib) • Rozlytrek (entrectinib) • Augtyro (repotrectinib)
    12ms
    🔥E-learning from @DrEzraCohen on TRK fusion-positive thyroid cancers. KEY POINTS ✅#NTRK fusions = more common in paediatric vs adult #thyroid cancer ✅#NTRK2 fusions not seen ✅Different prognosis in NTRK1 vs NTRK3 fusion-positive thyroid cancer https://t.co/NMMjp4HiJc #MedEd (@PresOnc_Connect)
    NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • NTRK3 positive • NTRK fusion
    1year
    Interesting learning from @DrEzraCohen on #TRK fusion-positive thyroid cancers ✅#NTRK fusions more common in paediatric vs adult #thyroidcancer ✅#NTRK2 fusions not seen ✅Different prognosis in NTRK1 vs NTRK3 fusion-positive thyroid cancer https://t.co/6NePVisJwk #MedEd (@PresOnc_Connect)
    NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • NTRK3 positive • NTRK fusion
    1year
    .@TrialsArena covers our recent data at #ELCC23 for #taletrectinib in #Ros1 #nsclc: https://t.co/Hd9GEOzpcM (@AnheartTx)
    ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    taletrectinib (AB-106)
    1year
    @DavidHongMD discusses updated findings from an analysis of 3 trials which ultimately led to the approval of #larotrectinib for patients with solid tumors who harbor an #NTRK fusion. #lcsm | @MDAndersonNews https://t.co/k1oP43s5t8 (@TargetedOnc)
    Clinical
    |
    NTRK (Neurotrophic receptor tyrosine kinase)
    |
    NTRK fusion
    |
    Vitrakvi (larotrectinib)
    1year
    TRUST- I :Taletrectinib looks like most promising drug in ROS 1+! TRUST-II trial is open to recruitment at @OncomedHCSC. Contact us! @TrialingHealth @gonzalezlarriba #ELCC2023 (@moniiiii89)
    Clinical
    |
    ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    taletrectinib (AB-106)
    1year
    Taletrectinib for ROS1 patients #ELCC23 : high response rates (52% in pretreated pts), prolonged PFS in both pretreated (12m) and naive (33 m) patients, robust intracranial activity, activity against G2032R, and tolerable safety with low incidence of neurological AEs. @OncoAlert (@JulienMazieres)
    Clinical
    |
    ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    ROS1 G2032R
    |
    taletrectinib (AB-106)
    over1year
    New learning from @DrEzraCohen on #TRK fusion-positive thyroid cancers. KEY POINTS -#NTRK fusions = more common in paediatric vs adult #thyroid cancer -#NTRK2 fusions not seen -Different prognosis in NTRK1 vs NTRK3 fusion-positive thyroid cancer https://t.co/W3nDR66sYB #MedEd (@ntrkconnectinfo)
    NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • NTRK3 positive • NTRK fusion
    over1year
    New learning from @DrEzraCohen on TRK fusion-positive thyroid cancers. KEY POINTS -#NTRK fusions = more common in paediatric vs adult #thyroid cancer -#NTRK2 fusions not seen -Different prognosis in NTRK1 vs NTRK3 fusion-positive thyroid cancer https://t.co/BctFnKUlAS #MedEd (@ntrkconnectinfo)
    NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • NTRK3 positive • NTRK fusion
    over5years
    Entrectinib in NTRK and ROS1 fusión positive Metastatic Pancreatic Cancer, a new promising therapeutic opportunity, our experience published at JCO Precision Oncology @GarridoLagunaMD @ASCOPost @ASCO @JCO_ASCO https://t.co/Rj0WlpXpqP (@ChristianRolfo)
    Rozlytrek (entrectinib)